Table 1.

The potency of ABT-737 and carboplatin in cell proliferation/survival assays

Single agent
Combination with carboplatin
ABT-737, IC50 (μmol/L)ABT-737E, IC50 (μmol/L)ABT-737 (μmol/L)IC50 (μmol/L), no ABT-737IC50 (μmol/L), with ABT-737Combination index
A278014 ± 126 ± 23.011 ± 110 ± 11.2 ± 0.1
cisA278011 ± 128 ± 13.0110 ± 2089 ± 141.2 ± 01
IGROV-18.2 ± 1.123 ± 10.621 ± 410 ± 30.54 ± 0.04*
OVCAR-314 ± 327 ± 11.04.6 ± 0.92.7 ± 0.70.65 ± 0.05*
OVCAR-410 ± 227 ± 21.025 ± 1221 ± 90.93 ± 0.06
OVCAR-58.8 ± 0.925 ± 10.664 ± 1047 ± 90.80 ± 0.04
OVCAR-813 ± 127 ± 11.070 ± 1137 ± 70.61 ± 0.06*
SK-OV-313 ± 328 ± 11.030 ± 425 ± 40.90 ± 0.04
  • NOTE: The potency of ABT-737 or ABT-737E as single agents was measured in cell proliferation/survival assays (columns 1 and 2; mean ± SD, n = 4-11). To measure the sensitization of ovarian cancer cells to carboplatin, cells were simultaneously treated with carboplatin and the indicated concentration of ABT-737 (column 3) and the potency of carboplatin determined (columns 4-5; mean ± SD, n = 4-7). Combination index values (mean ± SD) are quoted at a fraction unaffected of 0.5, and where shown, are significantly different from unity.

  • * P < 0.001, paired t test.

  • P < 0.01, paired t test.